MONDAY, Nov. 18, 2024 (HealthDay News) -- For children with achondroplasia, oral infigratinib does not result in major safety signals and yields increased annualized height velocity and z score at a ...

BridgeBio (BBIO) announced that 18-month results from PROPEL 2, a Phase 2 trial of the investigational therapy infigratinib in children with ...

The oral FGFR1-3 selective tyrosine kinase inhibitor infigratinib was found to be safe and effective at the highest studied ...

Investigational therapy infigratinib in children with achondroplasia demonstrated positive phase 2 results in the PROPEL 2 clinical trial, according to an announcement from BridgeBio Pharma. 1 ...

In children with achondroplasia, endochondral bone growth, an essential process by which bone tissue is created, is negatively regulated due to a gain of function mutation in FGFR3. VOXZOGO, a C-type ...

Get detailed information on Orlistat, including pronunciation, uses, dosage guidelines, indications, and instructions on how and when to take it and when to avoid it. The updated prescription ...

Peer-Reviewed Manuscript Published in Journal of Medicinal Chemistry. In September 2024, a manuscript titled "Discovery of ...

A new targeted therapy aimed specifically at FGFR3, TYRA-300, is showing preliminary promise in patients with advanced FGFR3-altered bladder cancer.Partial responses have been seen in an ongoing phase ...

ABOUT Achondroplasia Achondroplasia is disease in which a genetic mutation of the fibroblast growth factor receptor type 3 (FGFR3) causes FGFR3 to be activated, resulting in an excessive influx of ...